Pharmaceuticals

Haleon (HLN): Pfizer Sells Stake in Consumer Healthcare Firm

Pfizer has finalized its exit from Haleon by selling its remaining stake for £2.5 billion, marking a significant milestone for the firm.

Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts

Gilead Sciences shares fall amid reports of potential federal funding cuts for HIV initiatives, raising concerns for investors.

AstraZeneca Stock (AZN): Transformative Acquisition in Cancer Care

AstraZeneca acquires EsoBiotec for up to $1 billion, enhancing its cancer treatment portfolio with innovative cell therapies.

The Biotech Stocks Tackling the World’s Most Common Cancer

Medicus Pharma (NASDAQ: MDCX) joins Roche, Regeneron, and Bristol-Myers in the 360i BCC market matrix. Discover its breakthrough innovation in skin cancer care.

KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress

KalVista announces promising third quarter results with sebetralstat's progress, pivotal for patients with hereditary angioedema.

TG Therapeutics Stock (TGTX): Advancing MS Treatment

TG Therapeutics announces key data presentations on BRIUMVI, its MS treatment, signaling growth potential for investors.

Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline

Enliven Therapeutics continues to progress in its oncology trials with key Phase 1 data readouts expected in 2025 and a strong cash runway into 2027—discover the latest updates now.

Mineralys Therapeutics Stock (MLYS): Strategic Offering to Fuel Growth

Mineralys Therapeutics has priced a public offering to raise $175 million to advance clinical development of innovative treatments.

Roche Stock (OTC: RHHBY): Strategic Collaboration for Obesity Treatment

Roche partners with Zealand Pharma to co-develop petrelintide, targeting the growing obesity market with promising therapeutic solutions.

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities

Takeda's revamped oncology strategy prioritizes key tumors and innovative partnerships, enhancing growth prospects and market positioning.

2Seventy Bio (TSVT): Surge Following Acquisition Announcement

2Seventy Bio jumps 77% as Bristol Myers Squibb announces a $5-per-share buyout. Learn how this deal reshapes biotech investing and what it means for you.

FAQs on Medicus Pharma's Interim Data Update - 6 March 2025

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a novel skin cancer treatment. Here are FAQs explaining this breakthrough.

Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a revolutionary skin cancer treatment. Key details on this major breakthrough.

High Demand, Few Options: The Skin Cancer Treatment Gap

Basal Cell Carcinoma is 7x more common than melanoma, yet patients remain underserved. Sun and fair skin fuel its rise. Explore a rising need for treatments.

Walgreens Boots Alliance Inc. (WBA): Upcoming Acquisition by Sycamore Partners

Sycamore Partners nears a $10B Walgreens buyout, potentially breaking up the retail giant. What it means for investors, market dynamics, and strategic shifts.